Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

The aim of this study was to assess the impact of the genetic pattern (GP) defined by the single nucleotide polymorphisms (SNPs) rs14158 of low-density lipoprotein receptor (LDLR) and rs12979860 of interleukin-28B (IL28B) genes on the outcome and features of hepatitis C virus (HCV) infection in patients with and without human immunodeficiency virus (HIV) coinfection. 314 HIV/HCVcoinfected and 109 HCV-monoinfected patients treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV), as well as 51 patients with HCV spontaneous clearance (SC), were included. Variations in both SNPs were determined by the TaqMan polymerase chain reaction (PCR) assay. In the 286 patients chronically infected by HCV genotypes 1 or 4, both rs14158 CC and rs12979860 CC were associated with a higher rate of sustained virological response (SVR), and these effects were complementary in both HCVmonoinfected and HIV/HCV-coinfected patients. Thus, 24 % of patients with rs14158/rs12979860 TT-TC/TT-TC, 33 % with TT-TC/CC, 44.2 % with CC/TT-TC, and 75.8 % harboring CC/CC attained SVR (p< 0.001). SC was associated with the IL28B genotype (66.7 % CC in SC vs. 42.6 % among those with chronic infection, p < 0.001) but not with the LDLR genotype. There was no association between GP and the plasma level of alanine aminotransferase (ALT) or the presence of advanced fibrosis. There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4. Thus, the predictive value of IL28B genotype is modulated by the LDLR genotype in both HCV-monoinfected and HIV/HCV-coinfected patients. This complementary effect of both genotypes is also observed on the plasma levels of low-density lipoprotein cholesterol (LDL-C).Fil: Di Lello, Federico Alejandro. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Virología; Argentina; Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España; Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina;Fil: Caruz, Antonio. Universidad de Jaén; España;Fil: Rallon, Norma I.. Hospital Carlos III. Departamento de Enfermedades Infecciosas. Unidad de Inmunogenética; España;Fil: Rivero Juarez, Antonio. Hospital Universitario Reina Sofía. Instituto Maimónides de Investigación Biomédica de Córdoba. Unidad de Enfermedades Infecciosas; España;Fil: Neukam, Karin. Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España;Fil: Barreiro, Pablo. Hospital Carlos III. Departamento de Enfermedades Infecciosas. Unidad de Inmunogenética; España;Fil: Camacho, Angela. Hospital Universitario Reina Sofía. Instituto Maimónides de Investigación Biomédica de Córdoba. Unidad de Enfermedades Infecciosas; España;Fil: Garcia Rey, Silvia. Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España;Fil: Rivero, Antonio. Hospital Universitario Reina Sofía. Instituto Maimónides de Investigación Biomédica de Córdoba. Unidad de Enfermedades Infecciosas; España;Fil: Soriano, Vicente. Hospital Carlos III. Departamento de Enfermedades Infecciosas. Unidad de Inmunogenética; España;Fil: Cifuentes, Celia. Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España;Fil: Macias, Juan. Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España;Fil: Pineda, Juan A.. Hospital Universitario Valme. Unidad de Enfermedades Infecciosas y Microbiología; España